UBP 301 is primarily used in neuroscience research as a selective antagonist for kainate receptors, specifically targeting the GluK1 subtype. This compound is instrumental in studying the role of kainate receptors in synaptic transmission, plasticity, and neurological disorders. Researchers utilize UBP 301 to investigate conditions such as epilepsy, chronic pain, and neurodegenerative diseases, as it helps in understanding the mechanisms underlying these pathologies. Additionally, it aids in distinguishing the functional contributions of GluK1 receptors from other glutamate receptor subtypes, providing valuable insights into their distinct roles in the central nervous system.